Sarcura Raises a 2.5 M€ Seed Round

Start-up advances their transformative manufacturing platform for autologous cell therapies

Sarcura GmbH, an Austrian early stage technology start-up, announces the completion of an oversubscribed seed round from a European group of venture capital investors, including IST cubeNina Capital and Axilium Capital, in addition to an AWS Seed financing grant.

Founded in 2019 by a visionary, interdisciplinary team, Sarcura combines microfluidics and silicon chip technology in order to transform industrial manufacturing of personalized cell therapies. The company’s office and laboratory is located at IST PARK, the technology park adjacent to the campus of IST Austria.

Therapies to Revolutionize Cancer Treatment

Daniela Buchmayr, co-founder and CEO of Sarcura says “cell and gene therapies will revolutionize cancer treatment, though the manufacturing of personalized cell therapies remains a major bottleneck for the industry and leads to very high costs. Sarcura brings processing and real time control to the cellular level in order to fully automate the manufacturing of these highly potent, living medicines. We joined forces with a world-leading research centre in the field of nanoelectronics to devise novel, innovative approaches and develop the urgently needed technology for the production of affordable high-quality cell therapies.”

Sarcura Co-Founders Franz Emminger, Daniela Buchmayr, Erwin Gorjup (due to COVID19 per Screen), Martin Fischlechner and team member Philipp Neumann

Florian Resch, Partner at IST cube, comments: “Sarcura combines an interdisciplinary founders team of accomplished scientists and experienced managers with a research-derived, innovative product for a growing market with a strong need. With this profile, the company fits perfectly into our investment scope of early-stage, science-based start-ups and spin-offs. The team addresses a clear pain point in the market and convinced us with their customer-centric, and technology savvy approach. We are happy to lead this investment round and are looking forward to the next steps together with the founders and fellow investors.”

Marta-Gaia Zanchi, Ph.D, Partner at Nina Capital, remarks: “Sarcura addresses the infrastructural need of a growing therapy market to reduce the costs and time of manufacturing cell therapies, in order to bring their life-saving potential to more cancer patients. By applying semiconductor technology embedded in microfluidic processing systems, Sarcura will bring real-time bioprocess control to the cellular level, finally enabling the transformation from industrial biotechnology to personalised medicine.”
“This new funding will allow us to continue the development of our first product, a GMP device for controlled cell isolation with integrated real time process and quality control”, adds Daniela Buchmayr, co-founder and CEO of Sarcura.

In the Media

Press Release (German, English)

Article on Trending Topics (German)

Article on der Brutkasten (German)

Contact

For more information, contact:
Sarcura GmbH
Daniela Buchmayr, CEO
daniela.buchmayr@sarcura.com
www.sarcura.com